The emerging roles of GPR35 in the cardiovascular system may implicate it as a novel contributor to cardiovascular dysfunction and a potential therapeutic target in cardiovascular disease, especially in hypertension and heart failure.1 Although GPR35 has been linked with cardiovascular disease, and a GPR35 knockout mouse has been reported to have an abnormal blood pressure phenotype, the consequences of GPR35 deficiency on cardiovascular function are yet to be examined thoroughly. Here, GPR35 is linked to heart failure.